FDA Does Not Approve TKI Surufatinib for Neuroendocrine Tumors

Drug manufacturer Hutchmed said the FDA sent the company a complete response letter indicating that the agency requires a multiregional clinical trial before approving the drug in the US.
News Alerts

source https://www.medscape.com/viewarticle/973228?src=rss

Comments

Post a Comment

Popular posts from this blog

Student Nurses Who Refuse Vaccination Struggle to Complete Degrees

Kaitlyn Hevner expects to complete a 15-month accelerated nursing program at the University of North Florida in Jacksonville in December. For her clinical training this fall, she’s working 12-hour shifts on weekends with medical-surgical patients at a hospital. But Hevner and nursing students like her who refuse to get vaccinated against covid-19 are in an increasingly precarious position. Their stance may put their required clinical training and, eventually, their nursing careers at risk. In early September, the Biden administration announced that workers at health care facilities, including hospitals and ambulatory surgery centers, would be required to receive covid vaccines . Although details of the federal rule won’t be released until October, some experts predict that student nurses doing clinical training at such sites will have to be vaccinated, too. Groups representing the nursing profession say “students should be vaccinated when clinical facilities require it” to complete ...
Read more

The Clinical Characteristics of Fractures in Pediatric Patients Exposed to Proton Pump Inhibitors

Concerns are growing about the usage of proton pump inhibitors (PPIs) and the incidence of fractures in adults. Few researche have looked into this risk in pediatric patients. This study compared fractures and fracture sites in pediatric patients who had been exposed to PPI to those who had not. Between July 1, 2011, and December 31, 2015, encounters for patients aged 6 months to 15.5 years were discovered in the Pediatric Hospital Information System database. Chronic diseases, disorders, or medicines that predispose to fracture were excluded. If a charge for PPI was documented, the interaction was categorized as a PPI encounter. PPI interactions were matched to non-PPI encounters on the basis of inclination. Following the initial contact, patients were assessed for hospitalizations due to fracture during a 2-year period. The PPI-exposed group had a statistically significant increased risk of fractures. After controlling for remaining differences in gender, ethnicity, encounter type, p...
Read more